These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 2578880

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase II trial cisplatin, doxorubicin, and cyclophosphamide (CAP) in the treatment of urothelial transitional cell carcinoma.
    Campbell M, Baker LH, Opipari M, Al-Sarraf M.
    Cancer Treat Rep; 1981; 65(9-10):897-9. PubMed ID: 7196800
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K, Higuchi A, Maruyama S, Minayoshi K, Fujii A, Itoh N, Hasunuma Y, Tanaka H, Izumi T.
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
    Hong RL, Sheen TS, Ko JY, Hsu MM, Wang CC, Ting LL.
    Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
    [Abstract] [Full Text] [Related]

  • 10. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
    Yoshida O, Kakehi Y, Arai Y, Tomoyoshi T, Okada Y, Matsuda T, Mikami O, Fukuyama T, Hida S, Okabe T.
    Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
    [Abstract] [Full Text] [Related]

  • 11. [Combination chemotherapy of advanced bladder cancer].
    Kiyohara H.
    Hinyokika Kiyo; 1986 Dec; 32(12):1925-30. PubMed ID: 3825829
    [Abstract] [Full Text] [Related]

  • 12. Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma.
    Mulatero C, McClaren BR, Mason M, Oliver RT, Gallagher CJ.
    Br J Cancer; 2000 Dec; 83(12):1612-6. PubMed ID: 11104554
    [Abstract] [Full Text] [Related]

  • 13. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S, Yeap B, Vogl S, Carbone P.
    Cancer; 1996 Feb 15; 77(4):733-42. PubMed ID: 8616766
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
    Tsavaris N, Kosmas C, Skopelitis H, Dimitrakopoulos A, Kopterides P, Bougas D, Stravodimos K, Mitropoulos D, Alamanis C, Giannopoulos A.
    J Chemother; 2005 Aug 15; 17(4):441-8. PubMed ID: 16167525
    [Abstract] [Full Text] [Related]

  • 16. Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study.
    Gagliano RG, Stephens RL, Costanzi JJ, Oishi N, Stuckey WJ, Grozea PN, Frank J, Crawford ED.
    Cancer Treat Rep; 1984 Aug 15; 68(7-8):1025-6. PubMed ID: 6430559
    [No Abstract] [Full Text] [Related]

  • 17. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
    Lin CC, Hsu CH, Huang CY, Cheng AL, Vogelzang NJ, Pu YS.
    J Urol; 2007 Jan 15; 177(1):84-9; discussion 89. PubMed ID: 17162009
    [Abstract] [Full Text] [Related]

  • 18. [Chemotherapy for advanced bladder cancer: clinical evaluation of chemotherapy for locally advanced or metastatic bladder cancer and adjuvant chemotherapy for deeply invasive bladder cancer following radical cystectomy].
    Uekado Y, Ogawa T, Yoshida T, Yamamoto S, Hirano A, Watanabe T, Shinka T, Ohkawa T.
    Hinyokika Kiyo; 1985 Aug 15; 31(8):1365-70. PubMed ID: 3841260
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of amsacrine (AMSA) in previously treated patients with advanced transitional cell carcinoma of the urothelium: a National Bladder Cancer Collaborative Group A study.
    Trump DL, Loening S, Ahmed SW, Wajsman Z.
    Cancer Treat Rep; 1983 Sep 15; 67(9):845-6. PubMed ID: 6688377
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.